respiratory oncology haematology
EPIPHANY Index for PE in Cancer
Predicts clinical outcome of pulmonary embolism (PE) in cancer patients. Guides management intensity (outpatient vs admission vs ICU) and anticoagulation decisions.
References
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Sildenafil · PDE5 Inhibitor — Pulmonary Arterial Hypertension
- Dalteparin · Low Molecular Weight Heparin — VTE Treatment / Cancer-Associated Thrombosis
- Nitric Oxide (Inhaled — iNO) · Selective Pulmonary Vasodilator
- Enoxaparin (LMWH) · Anticoagulant
- Selexipag · Pulmonary Arterial Hypertension
- Macitentan · Pulmonary Arterial Hypertension
Pathways
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.